ITGAX and neoplasm: Consistent with expectation, immunofluorescence staining of CD11c in tumor-draining LNs showed that anlotinib treatment reduced DC number in LNs (Fig. 6a, c), which may be attributed to the decreased density of tumor-associated LVs.